Showing posts with label medicine. Show all posts
Showing posts with label medicine. Show all posts

Thursday, December 5, 2024

Ivermectin vs. Cancer



This page grew out of my Ivermectin vs. COVID-19 page.  While collecting links on that subject I ran across these papers on ivermectin and cancer.

The drug shows some amazing potential as a safe, non-toxic, treatment that can be used as an alternative, or addition, to chemotherapy.  Many of these papers describe ivermectin as killing cancer cells without harming healthy cells.  A wondrous drug indeed!

On a cautionary note, a study has found that a significant percentage of people (16% in the small study) have a genetic mutation that inhibits the metabolism of ivermectin.  In those patients, side effects such as “delirium-like behavior, agitation, aggressive attitude, and altered state of consciousness” occurred.  No such side effects occurred in people without the mutation.

Papers

Cancers in general.

Repurposing Vermicide Ivermectin as Medicine in Oncology to Treat Cancer- The Silent but Accessible Role Player in Sustainable Innovation

Inhaled Ivermectin-Loaded Lipid Polymer Hybrid Nanoparticles: Development and Characterization

Ivermectin and its synthetic derivatives – A new class of anticancer agents

Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy

Ivermectin A Potential Repurposed Anti-Cancer Therapeutic

Ivermectin: The future of Cancer Treatment

Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador

Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway

Ivermectin Enhanced Antitumor Activity of Resiquimod in a Co-loaded Squalene Emulsion

Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy

Synergistic Anti-tumor Effect of Dichloroacetate and Ivermectin

Ivermectin: Potential Repurposing of a Versatile Antiparasitic as a Novel Anticancer

Ivermectin, a potential anticancer drug derived from an antiparasitic drug

Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT‐TCF pathway responses in human cancer

Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models

Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug

Inhibition of TMEM16A Ca2+-activated Cl− channels by avermectins is essential for their anticancer effects

Ivermectin kills cancer cells via catastrophic changes in the endoplasmic reticulum structure

Old wine in new bottles: Drug repurposing in oncology

Long-Lasting WNT-TCF Response Blocking and Epigenetic Modifying Activities of Withanolide F in Human Cancer Cells

Lung cancer

Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer

Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells

Multiple myeloma

Assessing the potential of ivermectin against t(4;14) multiple myeloma.

Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma

Pancreatic cancer

Ivermectin suppresses pancreatic cancer via mitochondria dysfunction

Prostate cancer

Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway

Integrated analysis reveals FOXA1 and Ku70/Ku80 as direct targets of ivermectin in prostate cancer

Breast cancer

Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model

   

Genotoxicity and Anti-Cancer Activity of Tamoxifen and Ivermectin Loaded Chitosan Nanoparticles Against MCF-7 Cell Line

   

STRUCTURAL AND MOLECULAR CHARACTERIZATION OF LOPINAVIR AND IVERMECTIN AS BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) INHIBITORS

   

Ivermectin Induces Oxidative Stress and DNA Damage in Breast Cancer Cells

   


Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death

Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling

The PAK1-Stat3 Signaling Pathway Activates IL-6Gene Transcription and Human Breast Cancer Stem Cell Formation

Ivermectin as an inhibitor of cancer stem‑like cells

Bone cancer 

Repurposing Ivermectin to augment chemotherapy’s efficacy in osteosarcoma 

Ovarian cancer 

Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches 

Ivermectin: an ally to reverse P-glycoprotein-associated multidrug resistance in ovarian cancer 

Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells 

The Use of Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) to Study Ivermectin-Mediated Molecular Pathway Changes in Human Ovarian Cancer Cells 

The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer

Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine

Ivermectin inactivates the kinase PAK1 and blocks the PAK1- dependent growth of human ovarian cancer and NF2 tumor cell lines

SILAC quantitative proteomics analysis of ivermectin‐related proteomic profiling and molecular network alterations in human ovarian cancer cells

Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling

In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer

Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes

Multiomics-based energy metabolism heterogeneity and its regulation by antiparasite drug ivermectin.

Cervical cancer

Ivermectin-induced cell death of cervical cancer cells in vitro a consequence of precipitate formation in culture media 

Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway 

Esophageal squamous cell carcinoma (ESCC)

Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway

Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma

Renal cancer

Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage

Glioma

Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas

Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells

Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress

Nasopharyngeal carcinoma 

Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth

Melanoma

Macrocyclic Lactones Block Melanoma Growth, Metastases Development and Potentiate Activity of Anti–BRAF V600 Inhibitors

Suppressing ROS‐TFE3‐dependent autophagy enhances ivermectin‐induced apoptosis in human melanoma cells

Gastric cancer

Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer

Liver cancer

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways

Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice

Leukemia

Alendronate/lactoferrin-dual decorated lipid nanocarriers for bone-homing and active targeting of ivermectin and methyl dihydrojasmonate for leukemia

Codelivery of ivermectin and methyl dihydrojasmonate in nanostructured lipid carrier for synergistic antileukemia therapy

Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress

The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells

Colon cancer

Bladder cancer

Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage.

Ivermectin induces cell cycle arrest and caspase-dependent apoptosis in human urothelial carcinoma cells

Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug against Schistosoma-Associated Bladder Cancer Targeting Protein Signaling: Computational Drug Repositioning Approach

Clinical Trials

 Abstract PO1-19-07: A Phase I Study Accessing Immunotherapy Combination of Balstilimab and Ivermectin in Patients with Metastatic Triple Negative Breast Cancer

 List of Ivermectin/Cancer trials at clinicaltrials.gov

Articles

Ivermectin Reverses Breast Cancer!

Ivermectin for Parasites, but as a PAK1 Inhibitor for Autism, Cancer and Leukemia?




 



 

Posted by at 2 comments:
Labels: , , , ,

Tuesday, March 28, 2023

Ivermectin vs. COVID-19

Ivermectin vs. COVID-19



This is a collection of papers and resources I accumulated about the drug Ivermectin and its use against COVID-19.  I stopped updating this page when the subject became so politicized that even the science couldn't be trusted.  The drug is safe, cheap (patent-expired), widely available, FDA approved for many uses, and classified by the WHO as "essential medicine" (but not for COVID).  I think it became quite obvious that the vaccine manufacturers enlisted their scientists and media to discredit the drug.  Just look at their quarterly reports to understand why. 

I also became frustrated with the pro-ivermectin crowd when they completely ignored the genetic mutation that inhibits metabolism of Ivermectin (see this study for more details.)  This mutation occurs in a significant percentage of the population (16% in the small study).  Additionally, those who have this mutation often develop side effects with ivermectin use.  (These side effects cease when use stops.)  All of my attempts to bring this to the attention of the 'heavy-hitters' pushing ivermectin were met with stone silence.   This was personal for me as ivermectin had no effect on my wife.  I was very frustrated and confused about this until I found out about the mutation.

If Ivermectin doesn’t work for you, you may want to try Fluvoxamine.

For my page of Ivermectin news articles, click here.

For Ivermectin videos, click here.

For Ivermectin resources, click here.

While collecting these links, I also ran across numerous papers showing Ivermectin to be effective against cancer. 

Meta-analyses

Clinical Trials

Completed trials

Prophylaxis (Prevention)

Hospitalized and Outpatient

Reply to “Ivermectin Treatment May Improve the Prognosis of Patients with COVID-19”

COVID-19 Papers

Papers on other diseases (for more on Ivermectin vs. Cancer see here .)




Posted by at 22 comments:
Labels: , , , , ,
Subscribe to: Posts (Atom)